[Drug-induced immune thrombocytopenia: When both oxaliplatin and methylprednisolone are the culprits].

François Therme, Juliette Guiraud-Chaumeil, Géraldine Perkins, Margaux Lafaurie, Julien Maquet, Marie-Léa Piel-Julian, Sophie Voisin, Gérald Bertrand, Guillaume Moulis
{"title":"[Drug-induced immune thrombocytopenia: When both oxaliplatin and methylprednisolone are the culprits].","authors":"François Therme, Juliette Guiraud-Chaumeil, Géraldine Perkins, Margaux Lafaurie, Julien Maquet, Marie-Léa Piel-Julian, Sophie Voisin, Gérald Bertrand, Guillaume Moulis","doi":"10.1016/j.revmed.2025.03.427","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Drug-induced immune thrombocytopenia (DIIT) is a rare cause of immune thrombocytopenia, characterized by the formation of drug-dependent antiplatelet antibodies. DIIT can lead to life-threatening hemorrhage. The diagnosis is difficult, relying on the detection of antiplatelet antibodies in patient's serum exclusively in the presence of the implicated drug. The gold standard test is the monoclonal antibody immobilization of platelet antigens (MAIPA), although other techniques (flow cytometry and Luminex®) can be used.</p><p><strong>Patients: </strong>We report two cases of DIIT induced by both oxaliplatin and methylprednisolone.</p><p><strong>Results: </strong>The two patients were undergoing chemotherapy for colon malignancy, receiving a regimen including oxaliplatin following premedication with methylprednisolone. Thrombocytopenia occurred within hours after one infusion (both patients had received prior courses with this regimen). Immunological tests for both patients revealed antiplatelet antibodies in the presence of oxaliplatin (anti-GPIIbIIIa in the first observation, and polytypic in the second one) and methylprednisolone (anti-GPIbV in the first observation and GPIIbIIIa in the second one). After the discontinuation of the implicated drugs (and treatment with prednisone plus intravenous immunoglobulin for the first patient), both patients showed rapid improvement in a few days. Both patients continued chemotherapy without oxaliplatin and methylprednisolone. No relapse was observed during the follow up.</p><p><strong>Conclusion: </strong>DIIT are a rare cause of secondary immune thrombocytopenia. Diagnosis is complex, and the detection of drug-dependent antiplatelet antibodies in reference laboratories is essential. Oxaliplatin is a classical cause of DIIT. However, associated drugs like methylprednisolone can also be responsible for DIIT.</p>","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue de medecine interne","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.revmed.2025.03.427","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Drug-induced immune thrombocytopenia (DIIT) is a rare cause of immune thrombocytopenia, characterized by the formation of drug-dependent antiplatelet antibodies. DIIT can lead to life-threatening hemorrhage. The diagnosis is difficult, relying on the detection of antiplatelet antibodies in patient's serum exclusively in the presence of the implicated drug. The gold standard test is the monoclonal antibody immobilization of platelet antigens (MAIPA), although other techniques (flow cytometry and Luminex®) can be used.

Patients: We report two cases of DIIT induced by both oxaliplatin and methylprednisolone.

Results: The two patients were undergoing chemotherapy for colon malignancy, receiving a regimen including oxaliplatin following premedication with methylprednisolone. Thrombocytopenia occurred within hours after one infusion (both patients had received prior courses with this regimen). Immunological tests for both patients revealed antiplatelet antibodies in the presence of oxaliplatin (anti-GPIIbIIIa in the first observation, and polytypic in the second one) and methylprednisolone (anti-GPIbV in the first observation and GPIIbIIIa in the second one). After the discontinuation of the implicated drugs (and treatment with prednisone plus intravenous immunoglobulin for the first patient), both patients showed rapid improvement in a few days. Both patients continued chemotherapy without oxaliplatin and methylprednisolone. No relapse was observed during the follow up.

Conclusion: DIIT are a rare cause of secondary immune thrombocytopenia. Diagnosis is complex, and the detection of drug-dependent antiplatelet antibodies in reference laboratories is essential. Oxaliplatin is a classical cause of DIIT. However, associated drugs like methylprednisolone can also be responsible for DIIT.

[药物性免疫性血小板减少症:当奥沙利铂和甲基强的松龙都是罪魁祸首]。
药物性免疫性血小板减少症(DIIT)是一种罕见的免疫性血小板减少症,其特征是形成药物依赖性抗血小板抗体。DIIT可导致危及生命的出血。诊断是困难的,依赖于检测抗血小板抗体在患者的血清中只在涉及的药物存在。金标准测试是血小板抗原的单克隆抗体固定化(MAIPA),尽管其他技术(流式细胞术和Luminex®)也可以使用。患者:我们报告了两例奥沙利铂和甲基强的松龙引起的DIIT。结果:这两名患者正在接受结肠恶性肿瘤化疗,在预用药甲基强的松龙后接受奥沙利铂方案。一次输注后数小时内发生血小板减少(两名患者均接受过该方案的先前疗程)。两名患者的免疫学检查均发现奥沙利铂(第一次观察为抗GPIIbIIIa,第二次观察为多型)和甲基强的松龙(第一次观察为抗gpibv,第二次观察为抗GPIIbIIIa)存在抗血小板抗体。在停用相关药物后(第一个患者使用泼尼松加静脉注射免疫球蛋白治疗),两名患者在几天内均表现出快速改善。两名患者继续化疗,不使用奥沙利铂和甲基强的松龙。随访期间未见复发。结论:DIIT是继发性免疫性血小板减少症的罕见病因。诊断是复杂的,在参考实验室检测药物依赖性抗血小板抗体是必不可少的。奥沙利铂是DIIT的典型病因。然而,甲基强的松龙等相关药物也可能导致DIIT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信